Method for preparing for mantoux test with 2 te ppd-l in children with burdened allergical history

FIELD: medicine.

SUBSTANCE: before Mantoux test with 2 TE PDD-L, Ergoferon preparation is used in the infants infected with tuberculosis mycobacteria with the suspected early period of primary tuberculosis infection and active tuberculosis infection, in a dose of 1 tablet 20-30 minutes before or after a meal, once a day for 45 days.

EFFECT: invention provides the complex preparation of frequently and chronically ill children with an allergic pathology, for Mantoux test with 2 TE PDD-L.

3 tbl, 2 ex

 

The invention relates to medicine, mainly tuberculosis and Pediatrics, can be used to improve diagnosis of tuberculosis infection in children.

It is known that the intensity of tuberculin reactions are affected by various non-specific factors that enhance or weaken the phenomenon of paralleli (Fletcher, I. N. New approaches to the diagnosis and prevention of pediatric tuberculosis / I. N. Fletcher, N. In. Debortoli // Probl. tubes. - 2002. - No. 4. - S. 3-5; Evaluation of DPPD, a single recombinant Mycobacterium tuberculosis protein as an alternative antigen for the Mantoux test / A. Campos-Neto [et al.] // Tuberculosis. - 2001. - 81, №5-6. - P. 353-358): the nature of power, klimatometeorologicheskim conditions, concomitant diseases, pediatric infectious diseases, various vaccinations, certain medications, a common allergic reaction of the organism, the phase of the ovarian cycle in girls, the individual nature of skin sensitivity (Mitino L. A. Tuberculin (lecture) / L. A. Mitino // Probl. tubes. - 1998. - No. 3. - P. 76-77; Fletcher, I. N. New approaches to the diagnosis and prevention of pediatric tuberculosis / I. N. Fletcher, N. In. Debortoli // Probl. tubes. - 2002. - No. 4. - P. 3-5). Marked effects on the results of the Mantoux test with 2 TE have adverse environmental factors: increased radiation background, the presence of harmful emissions of chemical plants.

Tuberculin alle�Gia refers to a type IV allergic reactions (classification of Jell and Coombs). This reaction is mediated by cells (delayed): T-dependent activation of macrophages, eosinophils and other cells. Based on the nature paraallergii have allergic minded children in the formation of tuberculin sensitivity will participate not only IV and type I allergic reactions (acute reaction, mediated by IgE antibodies, sometimes IgG, together with mast cells, the reaction is known as immediate, anaphylactic, reagin). In addition, children suffering from diseases of ENT-organs, strengthen tuberculin sensitivity can circulating immune complexes that cause a type III allergic reactions (inflammation involving the complement, polymorphonuclear and other leukocytes). Enhancing of tuberculin sensitivity is observed in bronchial asthma, graves ' disease, rheumatic fever, brucellosis, pneumonia, scarlet fever, exacerbation of chronic diseases (tonsillitis, adenoiditis, hepatocholecystitis).

Reduction or complete extinction of tuberculin sensitivity seen with measles, whooping cough, malaria, viral hepatitis, cancer, Hodgkin's disease, myxedema, protein starvation. Skin reactions can be reduced with the use of antihistamines, corticosteroids, vitamins A, C, D, after vaccination against polio, measles.

In modern conditions acute �faces the question of categories and often chronically ill children this category accounted for as a risk group for TB, but given the increased level of infectious diseases (primarily acute respiratory viral infections) and medical allotment, vsledstvie the disease, do not always have the possibility of Mantoux test with 2 Tu PPD-L In connection with frequent viral diseases arises another problem is the influence of viral infection on the results of tuberculin, reducing the sensitivity to tuberculin, which, in turn, may lead to missing of tuberculosis infection.

Currently such immunopathological status, as a violation of the anti-infective protection, Allergy, autoimmune processes, have become a frequent occurrence. According to T. I. Aduhene et al. (2004) they underlie a wide range of human diseases, determining the nature and severity of the latter, because the immune system is a critical factor in the development of various pathological processes in the body. This helps to identify groups of children at increased risk of infection and tuberculosis.

The main method of active detection of tuberculosis infection in children in our country remains Mantoux test with 2 Tu PPD-L (K. I. Aksenova quality control Methods work on mass tuberculin diagnostics it/K. I. Aksana�and, E. S. By Ovsyankin, V. M. Alexandrov//Probl. tubes. - 2002. - No. 2. - S. 3-5; TB sensitivity in children of early and preschool age / E. M. Guseva [et al.]//Probl. tubes. - 2001. - No. 1. - P. 15-17; Fletcher, I. N. New approaches to the diagnosis and prevention of pediatric tuberculosis/I. N. Fletcher, N. In. Debortoli//Probl. tubes. - 2002. - No. 4. - P. 3-5). Tuberculin allows, even in the face of mass BCG vaccination, to determine the main contingents of children and adolescents with superelevation and hypersensitivity to tuberculin to carry out targeted preventive measures.

General recommendations when the difficulties of interpretation of the nature of sensitivity to tuberculin: children subject to prior surveillance "0" group dispensary in TB dispensary with mandatory treatment and prevention paediatric plot (hyposensitization, sanitation foci of infection, deworming, achieving remission in chronic diseases) under the control of a children's specialist. Repeat tests (Mantoux test with 2 Tu PPD-L) in the clinic is carried out after 1-3 months. Decline after nonspecific treatment sensitivity to tuberculin indicates a non-specific nature of the Allergy. Children with frequent clinical manifestations are nonspecific and�largie Mantoux test 2 is recommended for THOSE patients receiving desensitizing agents within 7 days (5 days before performances and 2 days after). Conservation of sensitivity to tuberculin at the same level, or further increase, despite treatment and preventive measures, confirmed the infectious nature of allergies and require subsequent follow-up care of the child in a TB institution (Annex No. 4 to the decree of the Ministry of health of the Russian Federation dated 21.03.2003 No. 109 "manual on the use of tuberculin tests"). Evaluation of the effectiveness of this training, available informative sources, was conducted. The disadvantages of this method include the fact that when the training group is not considered frequently and chronically ill children.

The closest technical solution is a method of preparation for the Mantoux test with 2 Tu PPD-L in children with severe allergic anamnesis, with suspected early period of primary tuberculous infection and active tuberculosis infection in previously infected with Mycobacterium tuberculosis before placing Mantoux test with 2 Tu PPD-L is prescribed sorbent POLYSORB": children aged 1-7 years - 1,0 g of the drug, 7-14 - 2.0 g, over 14 years in 4.0 g, three times daily for 10 days (patent RU 2466730 C1, A61K 33/08, A61P 1/06).

The disadvantages of this method include the fact that the sorbent has an effect only on the gastrointestinal tract in the manifestation of the allergen�pathology and to reduce the frequency of functional disorders of the gastrointestinal tract, but does not affect the prevention of URTI in children because the drug has antiviral activity.

The technical result of the invention is to increase the information content and reduce the time of diagnosis of tuberculosis infection in children, including group and often chronically ill viral infections with allergopathology.

The claimed technical result is achieved in that the method of preparation for the Mantoux test with 2 Tu PPD-L in children with severe allergic anamnesis, with suspected early period of primary tuberculous infection and active tuberculosis infection in previously infected with Mycobacterium tuberculosis, including from the group and often chronically ill, before placing Mantoux test with 2 Tu PPD-L is used the drug Alferon one 1 pill 20-30 minutes before or after meals once a day for 45 days.

The developed method allowed to increase the information content of the Mantoux test with 2 Tu PPD-L in children, including group and often chronically ill and having allergic reactions to 1.6 times and contributed to the decrease in the level of sensitization in each 2 children.

In the recovery of frequently ill children (FIC) focuses on sanitation of foci of infection in the nasopharynx and prevention of respiratory infections (Efficiency of complex of nonspecific protection of children doshas�measuring age from respiratory viral infections / V. A. Slobodenyuk [et al.] / / Pediatrics. - 1989. - No. 3. - S. 111., Okamoto K. Therapy of chronic tonsillitis / K. Okamoto // Asian Med. J. Jap. - 1986. - Vol.29, No. 7. - P. 390-39).

Given the fact that the main role in the development of acute respiratory pathology belongs to viruses, this leads to a temporary imbalance in the immune system, in particular to the decrease of the functional activity of cells and disruption of the processes of interferonbeta. When conducting tuberculin among a group FIC, be aware that the results might not reflect the true picture in terms of TB infection, as we observed reduction of tuberculin sensitivity and the preservation of weakly positive results in children older than 3 years. Restoring the balance in cytokine and interferon status, because the imbalance indicates a tense functioning of the immune system and the possible depletion of reserves of anti-infective resistance in this group of children is the main focus when conducting immunocorrective therapy. In our opinion the inclusion of immunomodulators in the list of drugs to prepare for the Mantoux test with 2 Tu PPD-L will allow the diagnostic sample, extending the period between episodes of acute respiratory infections, and will enhance the informative value of diagnostic p�Oba. However, physiopedia have a limited ability to use a variety of immunotropic drugs, especially for children of early and preschool age.

For the purpose of preparing for Mantoux test with 2 Tu PPD-L children can be recommended as the safest drugs for long-term use. Alferon is antiviral and antihistamine drug with immunomodulatory properties. The drug has a broad spectrum of pharmacological activity and includes antiviral, immunomodulatory, antihistamines, anti-inflammatory activity, in this regard, we consider it appropriate to use it as a means of prevention and treatment of ARI in children with allergic tendencies, when conducting training to the Mantoux test with 2 Tu PPD-L, including young children.

Drug Alferon OOO "NPF "Materia Medica holding" (Russia), provided in the form of tablets for sucking. The active ingredients of the drug: antibody to gamma interferon person affinity-purified - 0,006 g, antibodies to histamine affinity-purified - 0,006 g, antibodies to CD4 affinity-purified - 0,006 g Pharmacotherapeutic group: antiviral agent, an antihistaminic agent. Registration number: mprm-007362/10.

Pharmacodynamics:

Spectrum of pharmacological activity Alferon includes protover�scurry, immunomodulatory, antihistamines, anti-inflammatory.

Experimentally and clinically proven efficacy of the components of Alferon in viral infectious diseases: influenza A (seasonal flu, avian influenza A/H5N1 and swine flu (A/H1N1) and influenza, acute respiratory viral infections (caused by viruses parainfluenza, adenovirus, respiratory syncytial viruses, coronaviruses), herpes virus infection (herpes labial, ophthalmic herpes, genital herpes, shingles, chickenpox, infectious mononucleosis), acute intestinal infections of viral etiology (caused by caliciviruses, coronaviruses, rotaviruses, enteroviruses), enterovirus and meningococcal meningitis, hemorrhagic fever with renal syndrome, tick-borne encephalitis.

The drug is used in the treatment of bacterial infections (pseudotuberculosis, whooping cough, yersiniosis, pneumonitis of different etiology, including atypical pathogens (M. pneumoniae, C. Pneumoniae, Legionella spp.), used for prophylaxis of bacterial complications of viral infections, prevents the development of superinfection. The use of the drug in pre - and post-vaccination period increases the effectiveness of vaccination, provides nonspecific prophylaxis of acute respiratory viral infections (ARI) and influenza m�ment of the formation of postvaccinal immunity. Alferon has preventive efficacy against SARS agrippinae etiology, prevents the development of intercurrent diseases in the post-vaccination period.

Components included in this product have the same mechanism of action in the form of increased functional activity of CD4receptor, the receptors for interferon-gamma (IFN-γ) and histamine, respectively; that is accompanied by a pronounced immunotropic effect.

It is experimentally proved that antibodies to interferon gamma: increase expression of IFN-γ, IFN α/β, and the associated interleukins (IL-2, IL-4, IL-10, etc.), improve the ligand-receptor interaction of IFN, restore cytokine status; normalize the concentration and functional activity of natural antibodies to IFN-γ, which is an important factor in natural antiviral tolerance of the body; stimulate interferonogenami biological processes: induction of expression of the antigens of major histocompatibility complex I, II types and Fc-receptors, activation of monocytes, stimulation of the functional activity of NK-cells, the regulation of immunoglobulin synthesis, activating a mixed Th1 and Th2 immune response.

Antibodies to CD4probably as allosteric modulators of this receptor, regulate the functional activity of CD4receptor�, that leads to the increase of the functional activity of CD4lymphocytes, the normalization of immunoregulatory index CD4/CD8and subpopulation composition of immune competent cells (CD3, CD4, CD8, CD16, CD20).

Antibodies to modify histamine histamine-dependent activation of Central and peripheral HI-receptors and thus reduce the tone of smooth muscles of the bronchi, decrease capillary permeability, which leads to reduction of duration and severity rinorei, swelling of the mucous membranes of the nose, coughing and sneezing, as well as a decrease in severity of infectious process related allergic reactions by inhibition of histamine release from mast cells and basophils, production of leukotrienes, synthesis of adhesion molecules, reduction of chemotaxis of eosinophils, and platelet aggregation in response to contact with the allergen.

The combined use of the components of the integrated product is accompanied by increased antiviral activity of its components (the instruction to the drug Alferon).

Given the mechanism of action of the drug, it is advisable its use in the preparation of the Mantoux test with 2 Tu PPD-L in children, including group and often chronically ill with allergic reactions. Now to prepare for the Mantoux test with 2 Tu PPD-L Alferon not �riminals.

We have investigated the informativeness of the proposed method, with its high efficiency.

A clinical study was conducted on the basis of the MUSES "metal CRH and Coos PA "TCEI No. 4, which was included 52 children aged 3 to 14 years, consisting on the dispensary account on the "0" group in a specialized institution, in accordance with the criteria of inclusion and exclusion.

Inclusion criteria: the presence of the changing nature of tuberculin sensitivity in the dynamics; the children who are on the "0" group DN; informed parental consent to participate in the study.

Exclusion criteria: age younger than 3 years; the presence of malignant tumors; hypersensitivity to the drug; patient participation in another study; the refusal of a patient to participate in the study.

The children were divided into groups depending on the corrective therapy:

- in the first (main) group supervision (group 1) consisted of 20 patients, in preparation for the Mantoux test with 2 Tu PPD-L in the background of allergen-specific diet prescribed "Alieron" in the age dosage for 45 days prior to the test;

second, the comparison group (group 2) consisted of 32 patients who preparation was carried out according to the General recommendations with application at least 5 days prior to the test and 2 days after, antihistamines Wed�of DSTV (suprastin or tavegil, or diazolin, or cethrin in a dosage of age) following a hypoallergenic diet, sanitation foci of chronic infection.

The selection of patients into groups was performed by the method of randomization, the children in the groups were matched for age (group 1 5,6±0,6 years; group 2 5,3±0,4 years; p=0,605) and sex (tab.1), the nature of comorbidity (table.2), p>0,05.

Table 1
The distribution of children by gender
PaulBasic gr.%Gr. comparison%χ2p
boys8401443,70,0000,982
girls12601856,3

Table 2
Somatic health de�her
Signbasic gr. n=20 (%)gr. comparison n=32 (%)χ2p
Health groups:4,117of 0.128
I01 (3,1)
II14 (70)28 (87,5)
III6 (30)3 (9,4)
Physical development:2,8790,090
The weight deficit1 (5)9 (28,1)
Normal development19 (95)23 (71,9)
Clinical signs of immunodeficiency16 (80)16 (50)3,4980,061
Chronic pathology4 20) 2 (6,3)1,1320,287
Frequently and long ill children16 (80)22 (68,8)0,3230,570
Allergic20 (100)32 (100)-

All patients underwent clinical, laboratory, x-ray examination with registration in the "About" group and after 3 months (according to clinical guidelines) in accordance with Order No. 109 of the MOH of the Russian Federation of 21 March 2003

The effectiveness of training was evaluated on the basis of results of controlled clinical and laboratory examination and tuberculin held within 2 months after the end of the training to the Mantoux test with 2 Tu PPD-L.

According to the results of tuberculin average size of infiltration in the main group was 9.7±0.4 mm in the control group and 9.4±0.5 mm, p=0,696.

All children according to the results of clinical and radiological examinations showed no signs of local tuberculosis.

During the preparation for the Mantoux test with 2 Tu PPD-L with the use of the drug Alferon manifestations of adverse reactions to the drug were observed, all d�year the drug is well tolerated.

After preparation, the Mantoux test with 2 Tu PPD-L was not a reduction of tuberculin sensitivity by the average size of the infiltrate as in the main group and the comparison group (p>0,05) (tab.3).

Table 3
The results of tuberculin in the comparison group
Surveillance teamnThe average size of induration Mantoux test with 2 Tu PPD-L, mm
prior to the preparation of M±MConfidence intervalAfter preparation M±MConfidence interval
group 1209,7±0,4my 7.7 to 11.78,9±0,8from 5.5 to 12.3
group 2329,4±0,5of 6.5 to 12.39,6±0,75,7-13,5

Thanks to the results obtained in the main group, only 13 (65%) children were taken to the dispensary Ocampo VI group (risk group for TB) in TB facilities, in the comparison group 26 (81.3 per cent) child (χ2=0,975; p=0,323).

Evaluating the effectiveness of Alferon in frequently ill children with allergopathology (in the group of 1 child per year was recorded at 5.4±0.5 episodes SARS), found that during the observation period on the "0" group dispensary only 9 patients (45%) were recorded SARS with an average duration of 6.4±0.8 days, without complications. That resulted in 55% of cases in a timely manner to carry out the tuberculin skin test.

According to the results of the study, we noted both the increase and the decrease of sensitivity to tuberculin. In 11 patients (55%) registered a decrease of tuberculin sensitivity, in 6 patients (30%) registered the increase of sensitivity. In this case, patients at registration increased sensitivity to tuberculin was no marked increase in the absolute number of lymphocytes (up to training abs. the number of lymphocytes 3,3±0,4, after - 3,0±0,3; p=665), which confirms the absence of the stimulating effect of Alferon" on the immune system.

Thus, the preparation for the Mantoux test with 2 Tu PPD-L, conducted by the drug Alferon, more efficient General recommendations training in 1.6 times and reduces the level of sensitization in each 2 children.

The results of the study confirmed the high efficacy and safety of the drug Alferon that allows you to quickl� to recommend it for wide application in comprehensive preparation for the Mantoux test with 2 Tu PPD-L in children, including group and often chronically ill and having allergic diseases.

Examples of informativeness of drug Alferon to prepare for the Mantoux test with 2 Tu PPD-L in children may serve the following clinical examples.

Example 1. Natalia S., 06.07.00 G., was referred for a consultation in TCEI No. 4 with a diagnosis of Tubificidae increase in tuberculin tests? according to the results of tuberculin in April 2012 (the infiltration of 13 mm, in 2011 the infiltration of 5 mm). From the anamnesis of life child is organized, from the socio-intact family during the year were recorded 5 episodes of acute respiratory disease with protracted course, allergic anamnesis burdened, noted food Allergy. Contact with tuberculosis patients is not installed. According to the results of vaccination against tuberculosis was observed the formation of a scar 3 mm, Mantoux test with 2 Tu PPD-l of a year after vaccination, the infiltration of 5 mm, which is evidence of ineffective vaccination, revaccination was not. In the dynamics of the results of tuberculin noted the increase of tuberculin sensitivity by more than 6 mm, which may indicate the activity of tuberculosis infection, primary infection is established in 4 years. In August 2012 taken on record by the "0" group (diagnostic) dispensary, Prov�enny body of research showed no formation of tuberculosis. Recommended and conducted training to the Mantoux test with 2 Tu PPD-L: Alferon 1 tablet 1 time per day rate 45 days, hypoallergenic diet. According to the results of control examinations after training: Mantoux test with 2 Tu PPD-L from 12.11.12 - infiltration 8 mm (reduction of tuberculin sensitivity at 5 mm). On the basis of the results obtained established the absence of activation of tuberculosis infection (increased tuberculin sensitivity was due to the nonspecific component), which was also confirmed by negative result of Diaskintest®, the child was removed from the register with a diagnosis of Tubificidae. Parallely. During follow-up, episodes of SARS was not. Recommended: implementation of the Mantoux test with 2 Tu PPD-L in the background of allergen-specific diet by inclusion of the drug Alferon according to plan in terms of the General medical network.

Example 2. Alexander M., 31.05.05 G. has been referred to the TB Cabinet Separate CDH diagnosed with Virage tuberculin tests? according to the results of tuberculin in July 2012 (infiltration 6 mm - weakly positive reaction, and the first time registered a positive reaction). The child from socially intact family. History: frequent colds more than 4 times a year, allergic burdened anamnesis, chronic diseases not. Contact with �measuring TB is not installed. According to the results of vaccination against tuberculosis (in the hospital) there was observed the formation of a scar 5 mm in the first year after vaccination were recorded positive reaction to tuberculin, which indicated an effective vaccine. In the dynamics of Mantoux test with 2 Tu PPD-L for the first time positive, indicating a possible turn of the tuberculin tests, previously registered dubious reactions from 2008 In July 2012 taken on record by the "0" group (diagnostic) dispensary, volume of research conducted showed no formation of local tuberculosis. Recommended and conducted training to the Mantoux test with 2 Tu PPD-L: Alferon 1 tablet 1 time per day rate 45 days, hypoallergenic diet. According to the results of control examinations after training: Mantoux test with 2 Tu PPD-L from 22.10.12, hyperemia 3 mm (doubtful reactions), test with Diskinesia from 22.10.12 - reaction negative. On the basis of the results obtained established the absence of tuberculous infection, the child was removed from the register with a diagnosis are Not infected with M. tuberculosis.

Thus, on the background of effective training to the Mantoux test with 2 Tu PPD-L with the inclusion of the drug Alferon confirmed the absence of tuberculous infection in the second example, and the lack of activation in the first that was able to assess logius�call the situation and prevent the overdiagnosis of tuberculosis infection.

The developed method allows to increase the information content of the Mantoux test with 2 Tu PPD-L in children, including group and often chronically ill with allergopathology in 1,6 times, to reduce the level of sensitization in each 2 children and in half of the cases in a timely manner to carry out the tuberculin skin test, by reducing the frequency of acute respiratory viral infections.

The method of preparation for the Mantoux test with 2 Tu PPD-L in children with severe allergic anamnesis, with suspected early period of primary tuberculous infection and active tuberculosis infection in previously infected with Mycobacterium tuberculosis, characterized in that in children, including group and often chronically ill, before placing Mantoux test with 2 Tu PPD-L is used the drug Alferon one 1 pill 20-30 minutes before or after meals once a day for 45 days.



 

Same patents:

FIELD: medicine.

SUBSTANCE: before Mantoux test with 2 TE PPD-L, general advice for phthisiologist-controlled preparation of the infants are given. That is added with prescribing the immunomodulatory preparation Anaferon for children aged 1 year and older 1 tablet 20-30 minutes before and after meals once a day for 30 days.

EFFECT: invention provides the complex preparation of frequently and chronically ill children for Mantoux test with 2 TE PDD-L.

3 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to biotechnology, specifically to immunostimulating compounds and may be used in medicine. An immunostimulating peptide of an amino acid sequence XLYDKGYTSKEQKDCVGI, where N-terminal X is N-acetylalanine, and may be covalently linked to fatty acids, selected from C2-C25, to form PDAG (peptidyl-2,3-diacylglycerides). The resulted compound may be included in pharmaceutical formulations for stimulating an immune response.

EFFECT: invention provides efficient stimulation of an immune response in subjects and may enhance the immunogenicity of the antigenic peptide when administered with PDAG.

29 cl, 10 dwg, 9 ex

FIELD: medicine.

SUBSTANCE: first stage involves a cervical uterine repair by staged dissection on the 5-7th menstruation day in a combination with laser destruction of exophytic condylomas. Laser light power is 6-9 Wt, spot diameter is 1.5 mm, and exophytic condylomas penetration is 1-1.5mm. The second stage involves the immunomodulatory therapy.

EFFECT: method enables increasing the clinical effectiveness by recovering the immunological homeostasis of the uterine cervix by potentiating two effects: recovering archtechtonics of the cervical canal and immunomodulatory therapy.

4 tbl, 2 ex

Fingolimod salts // 2543621

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new 2-amino-2-[2-(4-C2-20alkylphenyl)ethyl]propan-1,3-diol salts specified in tartrate, lactate benzoate, succinate, malonate, acetate and propionate in the crystalline form. Each of the above salts is characterised by powder X-ray pattern data. Compounds in the therapeutically effective amount can be used in treating autoimmune diseases.

EFFECT: crystalline salts of the present invention possess higher stability, better solubility, more convenient to store and handle.

11 cl, 7 dwg, 1 tbl, 10 ex

FIELD: pharmacology.

SUBSTANCE: invention mainly relates to a food composition, including punicalagins.

EFFECT: improved action in respect to health improvement.

8 cl, 1 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of organic chemistry, namely to heterocyclic compound of general formula (I) or to its pharmaceutically acceptable salt, acid salt or stereoisomer, where Y: NRa and N+R1R2X-; Z: bond, -(CH2)p, -CHOH, -CH=CH-, -C≡C-, -CONH- and -CO-; Rb: C1-C8 alkyl, C2-C8 alkenyl, C6-C10 aryl, -NR5R6,: , and ; with each alkyl, alkenyl and aryl, representing Rb, possibly, contains 1-3 substituents, selected from C1-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkyl, C1-C4 alkoxy, C6-C10 aryl, 5-, 6- and 7-membered heterocyclyl, containing 1-3 heteroatoms, selected from nitrogen, oxygen and sulphur, halogen, -OH, -NH2, -CN and -NO2; Rc: halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkinyl, C3-C10 cycloalkyl, C3-C8 cycloalkenyl, C1-C4 alkoxy, C6-C10 aryl, 5-, 6-, 7- and 8-membered monocyclic heterocyclyl, containing 1-3 heteroatoms, selected from nitrogen, oxygen and sulphur, 9- and 10-membered bicyclic heterocyclyl, containing 1-3 heteroatoms, selected from nitrogen, oxygen and sulphur; with C1-C6 alkyl, C2-C6 alkenyl C2-C6 alkinyl, C3-C10 cycloalkyl, C3-C8 cycloalkenyl, C6-C10aryl, 5-, 6-, 7-, 8-membered monocyclic heterocyclyl and 9- and 10-membered bicyclic heterocyclyl, representing Rc, possibly contain 1-5 substituents, selected from the group, consisting of C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C3-C6 cycloalkyl, C4-C8 cycloalkenyla, halogen, -OH, -NH2, C6-C10 (A)(A')(A")(A'")aryl, (A)(A')(A")(A'")heterocyclyl, containing 1-3 heteroatom, selected from nitrogen, oxygen and sulphur, NR14R15, (CH2)pNR14R15, -CN, -NO2, oxo, -COOR14, SOR14, SO2R14, SO2NR14R15, NR15SO2R16, COR14, CONR14R15 and NR15COR16; with each (A), (A'), (A") and (A'")independently absent or representing C1-C4 alkyl, and each heterocyclyl (A)(A')(A")(A'")heterocyclyl is independently selected from the group, consisting of 5-, 6-, 7- and 8-membered monocyclic heterocyclyl, containing 1-3 heteroatoms, selected from nitrogen, oxygen and sulphur, and 9- and 10-membered bicyclico heterocyclyl, containing 1-3 heteroatoms, selected from nitrogen, oxygen and sulphur; the remaining radicals have values given in i.1;and on condition that, if Rc represents heterocyclyl, said heterocyclyl is bound directly through carbon atom of heterocyclyl ring. Invention also relates to particular compounds and to pharmaceutical composition based on formula (I) compound.

EFFECT: obtained are novel imidazopyrazine and imidazodiazepine derivatives, useful for prevention or treatment of disease or condition, severity of which is reduced by receptors to cannabinoids.

21 cl, 5 dwg, 4 tbl, 71 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to isoxazoline FAAH inhibitors of formula (I) or their pharmaceutically acceptable forms, wherein each of G, Ra, Rb, Rc and Rd has a value described in the present application, to pharmaceutical compositions, and methods of treating a FAAH-mediated condition.

EFFECT: developing the method of treating the FAAH-mediated condition.

32 cl, 22 tbl, 351 ex

FIELD: medicine.

SUBSTANCE: immunocorrective agent for the therapy of atherosclerotic diseases containing hawthorn blossom, common St. John's wort herb, as well as calcium stearate and silicone oxide taken in certain proportions.

EFFECT: agent is effective for the therapy of atherosclerotic diseases.

8 ex

FIELD: biotechnology.

SUBSTANCE: invention is a composition having antibacterial, immunostimulating, anti-allergic and anti-inflammatory action, containing bacterial waste products useful for human body, in the form of exometabolites and fermentolysis products, characterised in that it is a culture medium of lactic acid bacteria, containing laxarane in an amount of 5-10 g/ml, caseicyne, isracydine or their mixture and lectins in an amount of 0.05-2.5 mol/l, histamine in an amount of 0.8-2.0 mmol/l and monocarboxylic fatty acid with an unbranched chain, namely, acetic acid, propionic acid, butyric acid and valeric acid - in an amount of 10-20 mg/ml.

EFFECT: expanding the range of agents having complementary antibacterial, immunomodulating, anti-allergic and anti-inflammatory action.

4 cl, 5 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises giving to calves to drink the tincture of the combination herbal medicinal product - the grass of St. John's wort, meadowsweet, common yarrow, common nettle, rhizome of leather bergenia, root and rhizome of marsh cinquefoil, Scotch pine needles. At that the tincture fermented with microorganisms "EM Kurung" is used. The tincture is prepared by mixing 200 ml the tincture of the combination herbal medicinal product with 40 ml of the finished product "EM Kurung" and maintaining at the temperature of 18-20°C during the day, followed by filtration. EM-preparation "Baikal EM 1" is given to dry cows for 30 days prior to calving as a single dose in a dose of 30 ml/head. Mixoferon, sedimin and nitamin are additionally prescribed to new-born calves according to the following schedule: from the second feeding the tincture of the combination herbal medicinal product is watered with colostrum, fermented with microorganisms of EM-preparation "EM Kurung" at a dose of 150 ml/head dualfold for 10 days. On the 1, 2 and 8 day of life, mixoferon is injected intramuscularly at a dose of 9 ml/head. On the 1 and 8 day of life - nitamin and sedimin at a dose of 4 ml/head.

EFFECT: use of the claimed method enables to increase the immunobiological reactivity, energy of growth, provides prevention of gastrointestinal diseases of new-born calves.

4 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: before Mantoux test with 2 TE PPD-L, general advice for phthisiologist-controlled preparation of the infants are given. That is added with prescribing the immunomodulatory preparation Anaferon for children aged 1 year and older 1 tablet 20-30 minutes before and after meals once a day for 30 days.

EFFECT: invention provides the complex preparation of frequently and chronically ill children for Mantoux test with 2 TE PDD-L.

3 tbl, 2 ex

FIELD: pharmacology.

SUBSTANCE: invention represents methods for treatment of an autoimmune disease, including introduction of a pharmaceutical composition to a subject, containing a pharmaceutically acceptable carrier and a humanised anti-CD4-antibody, capable of activating regulatory T-cells CD4+CD25+, where the specified antibody contains a V-domain of an H-chain, containing sequences DCRMY, VISVKSENYGANYAESVRG and SYYRYDVGAWFAY, and a V-domain of an L-chain, containing sequences RASKSVSTSGYSYIY, LASILES and QHSRELPWT. The specified composition is introduced to a subject with frequency from daily intake to introduction every 31st day and with a dose of a humanised anti-CD4-antibody from 20 to 200 mg, or from 8 to 60 mg/m2 of the subject body surface area, or from 0.2 to 2 mg/kg. This invention also discloses a set for treatment of an autoimmune disease, which contains multiple doses of the above pharmaceutical composition.

EFFECT: invention makes it possible to introduce a pharmaceutical composition containing a humanised anti-CD4-antibody, with more lengthy intervals of dosing and in higher doses, not losing the therapeutical effect and not causing side effects.

59 cl, 41 dwg, 27 tbl, 9 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to biotechnology and represents methods of treating an autoimmune disease involving administering into an individual a pharmaceutical composition containing a pharmaceutically acceptable carrier and a humanised anti-CD4-antibody, able to activate the regulatory C-cells CD4+CD25+, wherein the above antibody contains V-domain of H-chain containing the sequences DCRMY, VISVKSENYGANYAESVRG and SYYRYDVGAWFAY, and V-domain of L-chain containing the sequences RASKSVSTSGYSYIY, LASILES and QHSRELPWT; the above composition is administered subcutaneously into the individual in a dose of the humanized anti-CD4-antibody 20 to 200 mg or 8 to 60 mg/m2 of the individual's body surface, or 0.2 to 2 mg/kg. The present invention also discloses the pharmaceutical compositions applicable in the above methods of treating the autoimmune disease.

EFFECT: invention enables administering the pharmaceutical composition containing the humanised anti-CD4-antibody in higher doses losing no therapeutic effect and causing no intensification of any side effects.

46 cl, 20 dwg, 21 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: copolymers of hetero-chain aliphatic poly-N-oxides of general formula (I) , where R=N, CH; x=2-4; y=0, 2; n=10-1000; q=(0.1-0.9)n; z=(0.1-0.9)n. Copolymers possess anti-oxidant action, therapeutic action as detoxicant and immunomodelling agent. Copolymers of formula (I) can be used as immunomodulating carrier for obtaining vaccinating medication and as carrier of medications for obtaining medications.

EFFECT: copolymers of hetero-chain aliphatic poly-N-oxides represent novel class of compounds possessing wide spectrum of pharmacological and vaccinating action, aimed at increase of safety in application, increase of technological and economical effectiveness and ecological safety of production of medications.

20 cl, 2 dwg, 13 tbl, 22 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to ophthalmology, and can be used in treating the patients with macular oedemas of various geneses. That is ensured by the therapy that starts with 6 sessions of plasma exchange every 2 days. It is followed by a single intravitreal introduction of antivasoproliferative preparation Avastin in dosage 1.25 mg or Lucentis in dosage 0.5 mg.

EFFECT: method allows improving clinical effectiveness combined with reduced intravitreal introduction of the antivasoproliferative preparations, due to involving pathogenetic mechanisms, namely elimination of pathological immune complexes, stabilisation of pro- and anti-inflammatory cytokines.

2 cl, 2 ex

FIELD: medicine; oncology.

SUBSTANCE: invention can be used for treatment of an acute myelogenetic leukemia or myelodysplastic syndrome. For this purpose use a combination of preparations hemetuzumab ozohamicin, daunorubicin and cytarabinum in certain doses and regimens.

EFFECT: invention promotes effective treatment of the specified diseases due to synergistic effect at influence of these preparations on an organism.

2 cl, 2 ex

FIELD: medicine; immunology.

SUBSTANCE: sorbent is offered to remove immunoglobulin from human blood plasma. This sorbent contains agarous matrix covalently combined with ligand. As a ligand at that it contains F(ab)2 fragments of specific affinely-purified polyclonal antibodies blocking human immunoglobulin G. Sorbent is actually biologically inert, biocompatible agarous matrix. Sorbent is characterized with higher sorptive capacity and safety of immunosorbents used practical purposes, specifically for therapeutic aphaeresis in comparison to well-known polyclonal bodies based sorbents.

EFFECT: considerable reduction of prospective immunological response of human body for foreign protein.

1 ex, 1 tbl

FIELD: medicine, oncology.

SUBSTANCE: method includes the consecutive stages: (a) administration of at least one dose of anti-angiogenic cyclo-(arginine-glycine-asparagine acid)-containing pentapeptide (pentapeptide cRGD), such as cyclo-(Arg-Gly-Asp-D-Phe-[N-Me]-Val); (b) administration of anti-tumor effective amount of radio immunotherapeutic agent(RIT) not later than in 1 hour following administration of pentapeptide cRGD at stage (a); and (c) administration of at least two additional doses of pentapeptide cRGD, where the first additional dose is administered within 2 days after RIT and each additional dose of pentapeptide cRGD is administered with intervals between doses not more than 2 days.

EFFECT: invention provides the synergic effect in regard to apoptosis of tumor cells and endothelial cells of tumor vessels.

30 cl, 6 dwg, 2 tbl

FIELD: medicine, molecular biology, antibodies.

SUBSTANCE: invention relates to an antibody raised against CCR5 and comprising: (i) two light chains wherein each light chain comprises product of plasmid expression and designated as pVK:HuPRO140-VK (ATCC - PTA-4097), and (ii) two heavy chains wherein each heavy chain comprises product of plasmid expression and designated as pVg4:HuPRO140 HG2-VH (ATCC - PTA-4098), or plasmid designated as pVg4:HuPRO140 (mut B+D+I)-VH (ATCC - PTA-4099), or fragment of such antibody binding with CCR5 on a human cell surface. Invention relates to nucleic acid encoding light and heavy chains of antibody, expression vector, cell-host transformed with at least one vector, and a method for preparing antibody. Antibody is used as an active component in composition used for inhibition of infection of cells CD4 + HIV-1, and to a pharmaceutical composition used in treatment of a patient with HIV-1 infection. Also, invention relates to antibody conjugate against CCR5 and its using. Use of antibodies provides enhancing effectiveness of prophylaxis and treatment of HIV-1 infection.

EFFECT: valuable medicinal properties of antibody.

31 cl, 23 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: method involves applying effective doses of epidermis growth factor receptors antagonists being active ingredient in drug for inhibiting various types of resistant human tumors. The epidermis growth factor receptor antagonists are combined with other chemotherapeutic agents like Cisplatin, Irinotecan or ionizing radiation.

EFFECT: enhanced effectiveness of treatment.

50 cl, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of biochemistry, in particular to cyclic peptide, capable of inducing antibody response. Peptide consists of formula X2X3VGSNK-Z or X3VGSNKG-Z, where X2 represents E, G, Q or K, X3 represents D or N and Z represents agent, stabilising bent, present inside peptide sequence, with peptide being cyclised by covalent bonding of N-end amino acid with Z, where Z represents peptide fragment YNGK. Conjugate, containing said cyclic peptide, conjugated with immunogenic carrier molecule is also claimed. peptide and conjugate, which contains it, can be applied for production of medication or as vaccine against Alzheimer's disease. Methods of obtaining cyclic peptide and conjugate are also claimed.

EFFECT: invention makes it possible to obtain improved, less toxic vaccine against Alzheimer's disease.

8 cl, 11 dwg, 1 tbl, 2 ex

Up!